Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 16, 2025--
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug.
Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2
The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies.
'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.'
The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication.
'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.'
The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.'
To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster.
1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas.
2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250616585193/en/
CONTACT: Media Contact Information:
Ned Glascock
E-mail:[email protected]
Website:www.thermofisher.comErin Morton
E-mail:[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Thermo Fisher
Copyright Business Wire 2025.
PUB: 06/16/2025 08:15 AM/DISC: 06/16/2025 08:14 AM
http://www.businesswire.com/news/home/20250616585193/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
21 minutes ago
- Bloomberg
Coty Shares Surge on Report Company Looking to Sell Off Units
Shares of Coty Inc. jumped following a report the embattled cosmetics and perfume company is contemplating splitting up the business. The stock rose as much as 13% after Women's Wear Daily said the company is in the early stages of a sale process, citing 'multiple industry sources' it didn't identify.
Fast Company
22 minutes ago
- Fast Company
New Trump Mobile brand offers 5G plan and MAGA-themed gold phone
For years, President Trump has had a famous affinity for his personal cell phone. He's been known to rely on the device to contact world leaders, arrange business deals, and answer calls from a flurry of daily unknown numbers —often in spite of potential security threats. Early this month, The Atlantic called him 'the ultimate Phone Guy' in an article detailing his aides' concerns around his phone use. Now, The Trump Organization appears to be spinning Trump's 'Phone Guy' reputation into yet another business venture: a mobile service and smartphone brand called Trump Mobile. According to a press release published Monday, Trump Mobile—also known as 'T1 Mobile'—is a 'new cellular service designed to deliver top-tier connectivity, unbeatable value and all-American service.' The release notes that the brand will provide 5G service through all three major cellular carriers (AT&T, T-Mobile, and Verizon). Its flagship offering, 'The 47 Plan,' costs $47.75 per month and includes features like roadside assistance, unlimited data, and telehealth services. Alongside the cellular plan, Trump Mobile is debuting a $499 gold smartphone called the 'T1 Phone,' slated for release this fall. Gold all the way down The site itself features an ultra-simple, almost bare-bones design—including a blocky, all-caps sans-serif font, gold accents, and several stock images of smiling customers. Along a similar vein, available renderings of the T1 Phone include a mocked-up home screen with the slogan ' Make America Great Again ' rendered beneath a 'Trump Mobile' logo, as well as the back of the phone, which is embossed with an image of the American flag and the 'T1' symbol. The phone's operating system is an Android 15. While it's unclear exactly how the phone's gold hue has been achieved, the look echoes an emerging design theme from Trump's second term. In 2004, Trump told reporters that the reign of Louis XIV represented his 'favorite style,' and since taking office this January, echoes of that gilded inspiration have appeared in several places around the President. In the Oval Office itself, Trump has implemented a slew of gold decor. Last month, he accepted a luxury jet from Qatar that's decked out in gold furniture. And last week, Trump debuted a physical 'gold card' visa scheme as a dubious way to allow wealthy immigrants into the U.S. Now, the T1 Phone, like the countless other pieces of Trump merch before it, will serve as a piece of walking advertising for the President's personal brand. Blurred lines between office and profit The Trump Organization's new phone business is the most recent in a large existing catalog of licensing deals and branded-merch agreements that rely on the President's likeness—from guitars and Bibles, to watches, sneakers, and fragrances. According to a financial disclosure form filed last Friday, these income streams represented more than $8 million in profits for the President in 2024. In order to avoid potential conflicts of interest, The Trump Organization (which manages the majority of Trump's business ventures) reported ahead of Trump's inauguration that control of the company would be given to his children for the duration of his term. Based on the press release, Trump Mobile will be spearheaded by Donald Trump Jr. and Eric Trump. And, because the brand uses the Trump name through a trademark license, its website notes that 'its products and services are not designed, developed, manufactured, distributed or sold by The Trump Organization or any of their respective affiliates or principals.' Still, experts say there are still plenty of ethical concerns around Trump's business ventures. This term, Trump stands to profit from holdings in cryptocurrency, real estate, social media, and consumer products, all of which are bolstered by his status as President. In an interview with Reuters, Paolo Pescatore, TMT analyst at PP Foresight, explained that this new cellular business presents new questions, given that Trump Mobile's actual commercial relationship with telecom players is 'unclear.' In a series of interviews this morning, Trump's sons indicated that Trump Mobile phones would be 'American-made,' with a call center located in St. Louis, Missouri. This emphasis on American manufacturing, echoed on the website, comes in the wake of Trump's sweeping tariffs, which has put phone manufacturing in its crosshairs, given that most phones (and phone components) purchased in the U.S. are made in China, Vietnam, South Korea, and India. Trump Mobile did not immediately respond to Fast Company 's request for clarification on the phones' manufacturers, designers, and distributors. 'No one who has been paying attention could miss that President Trump considers the presidency a vehicle to grow his family's wealth,' Lawrence Lessig, a law professor at Harvard Law School, told Reuters of Trump Mobile. 'Maybe this example will help more come to see this undeniable truth.'
Forbes
22 minutes ago
- Forbes
How To Lead When Work Feels Uncertain and Overwhelming
From recent graduates to seasoned executives, I hear it every day in coaching sessions, advisory calls, and off stage: people searching for ways to steady themselves, lead with resilience, and offer stability to others - even as they quietly wonder, 'Will I make it through this?' or 'Do I even want to keep doing this anymore?' There's the recent grad whose job offer evaporated in an unstable economy. The middle manager stretched thin, unsure if their role is next to be automated. The C-suite executive walking a tightrope, wanting to signal a commitment to inclusion while avoiding scrutiny. And employees interpreting every shift as a sign of risk or retaliation. In today's workplace, everyone is on edge. We're not just navigating constant change and uncertainty - we're navigating the fragility born of it. Whether you're leading a team or stepping into leadership, the old playbook isn't enough. VUCA - short for Volatility, Uncertainty, Complexity, and Ambiguity, once helped leaders make sense of disruption. But today's challenges run deeper. Coined by futurist Jamais Cascio, BANI - Brittle, Anxious, Nonlinear, and Incomprehensible - better captures the emotional and structural disarray shaping how we live and work. As Jonathan Kruse writes, managing volatility and uncertainty is no longer enough. We must confront the fragility embedded in how we work and lead. Journalist Jodi Kantor, speaking at Columbia University's 2025 commencement, pointed to the growing crisis of truth and the need for leaders who can make sense of the world: Leading through BANI shouldn't just be about surviving the moment. It should be about becoming the kind of sense-making leader this moment demands. These four practices can help - whether you're leading a team or leading yourself through a career transition - by building the resilience, grounding, agility, and discernment needed to thrive in today's world. Brittle systems look stable until they're hit with change. One surprise mandate, lost client, tech hiccup, and things crumble. Resilient leaders, by contrast, design for stress. They build stretch into their practices and systems, giving themselves and their teams space to sit in and normalize change, not perfection. Anxiety doesn't just live in our minds - it shows up in meetings, performance reviews, and how teams respond to change. Left unchecked, it can paralyze creativity and decision-making. But leaders can ground their teams by building psychological safety: a climate where people feel safe speaking up, admitting mistakes, and asking for help without fear of retribution. As Morra Aarons-Mele, author of The Anxious Achiever, writes: 'Work can make us anxious, because people are messy and stress is real. And that is ok. Challenges can fuel growth but only if we stop hiding our emotions and get the support we need.' The antidote isn't to eliminate anxiety. It's to name it, normalize it, and create steadying practices. In a nonlinear world, cause and effect are not always directly connected. In unpredictable times, it's less about rigid plans and more about learning quickly, adapting often, and staying responsive. The key is to flex your planning muscle in smaller doses, get input from across the organization, and treat every misstep as data you can use. We're surrounded by data but starved for clarity. Complexity doesn't have to lead to confusion. When things feel incomprehensible, great leaders translate complexity into purpose, shared understanding, and trust within teams. You can move from assuming understanding to actively verifying it. Your teams will thank you for it. Today's leaders - whether guiding teams or charting their next chapter - have an opportunity to redefine what leadership looks like in an age of fragility. When we lead with resilience, grounding, agility, and discernment, we make space for uncertainty, shape cultures that bend without breaking, and guide ourselves and others through change with clarity and courage.
